Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.lfs.2003.05.006
DC FieldValue
dc.titleTissue microarray study for classification of breast tumors
dc.contributor.authorZhang, D.-H.
dc.contributor.authorSalto-Tellez, M.
dc.contributor.authorChiu, L.-L.
dc.contributor.authorKoay, E.S.-C.
dc.contributor.authorShen, L.
dc.date.accessioned2012-02-01T05:23:44Z
dc.date.available2012-02-01T05:23:44Z
dc.date.issued2003
dc.identifier.citationZhang, D.-H., Salto-Tellez, M., Chiu, L.-L., Koay, E.S.-C., Shen, L. (2003). Tissue microarray study for classification of breast tumors. Life Sciences 73 (25) : 3189-3199. ScholarBank@NUS Repository. https://doi.org/10.1016/j.lfs.2003.05.006
dc.identifier.issn00243205
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/30352
dc.description.abstractClinical and pathological heterogeneity of breast cancer hinders selection of appropriate treatment for individual cases. Molecular profiling at gene or protein levels may elucidate the biological variance of tumors and provide a new classification system that correlates better with biological, clinical and prognostic parameters. We studied the immunohistochemical profile of a panel of seven important biomarkers using tumor tissue arrays. The tumor samples were then classified with a monothetic (binary variables) clustering algorithm. Two distinct groups of tumors are characterized by the estrogen receptor (ER) status and tumor grade (p = 0.0026). Four biomarkers, c-erbB2, Cox-2, p53 and VEGF, were significantly overexpressed in tumors with the ER-negative (ER-) phenotype. Eight subsets of tumors were further identified according to the expression status of VEGF, c-erbB2 and p53. The malignant potential of the ER-/VEGF+ subgroup was associated with the strong correlations of Cox-2 and c-erbB2 with VEGF. Our results indicate that this molecular classification system, based on the statistical analysis of immunohistochemical profiling, is a useful approach for tumor grouping. Some of these subgroups have a relative genetic homogeneity that may allow further study of specific genetically-controlled metabolic pathways. This approach may hold great promise in rationalizing the application of different therapeutic strategies for different subgroups of breast tumors. © 2003 Elsevier Inc. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.lfs.2003.05.006
dc.sourceScopus
dc.subjectBreast cancer
dc.subjectImmunohistochemistry
dc.subjectTissue microarray
dc.subjectTumor classification
dc.typeArticle
dc.contributor.departmentPATHOLOGY
dc.description.doi10.1016/j.lfs.2003.05.006
dc.description.sourcetitleLife Sciences
dc.description.volume73
dc.description.issue25
dc.description.page3189-3199
dc.description.codenLIFSA
dc.identifier.isiut000186176800003
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.